Cargando…

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Precision medicine has opened up a new era in the development of anti-cancer agents that is focused on identifying biomarkers predictive of treatment response regardless of tumor histology. Since 2017, the Food and Drug Administration has approved six drugs with histology-agnostic indications: pembr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iannantuono, Giovanni Maria, Torino, Francesco, Rosenfeld, Roberto, Guerriero, Simona, Carlucci, Manuela, Sganga, Stefano, Capotondi, Barbara, Riondino, Silvia, Roselli, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369092/ https://www.ncbi.nlm.nih.gov/pubmed/35955671 http://dx.doi.org/10.3390/ijms23158535

Ejemplares similares

NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives
por: Sganga, Stefano, et al.
Publicado: (2023)

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review
por: Rosenfeld, Roberto, et al.
Publicado: (2022)

1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19?
por: Iannantuono, G.M., et al.
Publicado: (2021)

Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?
por: Riondino, Silvia, et al.
Publicado: (2023)

Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation
por: Morelli, Cristina, et al.
Publicado: (2022)

Histology-Agnostic Drugs: A Paradigm Shift—A Narrative Review
por: Mansinho, André, et al.
Publicado: (2022)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
por: Cabel, Luc, et al.
Publicado: (2018)

Deep Domain Adversarial Learning for Species-Agnostic Classification of Histologic Subtypes of Osteosarcoma
por: Patkar, Sushant, et al.
Publicado: (2023)

The Bacillus Agnostic
Publicado: (1911)

γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
por: Frieling, Jeremy S., et al.
Publicado: (2023)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models
por: Riondino, Silvia, et al.
Publicado: (2019)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Agnostic Tendency in Doctors
Publicado: (1885)

Prostatic Neoplasia in the Intact and Castrated Dog: How Dangerous is Castration?
por: Schrank, Magdalena, et al.
Publicado: (2020)

Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress
por: Ferroni, Patrizia, et al.
Publicado: (2015)

Reference-agnostic representation and visualization of pan-genomes
por: Liang, Qihua, et al.
Publicado: (2021)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study
por: Restelli, Umberto, et al.
Publicado: (2017)

Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2023)

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)

Predictors for progression of metastatic prostate cancer to castration-resistant prostate cancer in Indians
por: Sureka, Sanjoy Kumar, et al.
Publicado: (2016)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2016)

Next Generation Sequencing in metastatic castrate-resistant prostate cancer
por: Adashek, Jacob J., et al.
Publicado: (2018)

Denosumab-induced hypocalcaemia in metastatic castrate-resistant prostate cancer
por: Gunawan, Florence, et al.
Publicado: (2019)

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
por: Bansal, Dhruv, et al.
Publicado: (2021)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer
por: Pobel, Cedric, et al.
Publicado: (2021)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rqcuhs59kmi3nqr04fam9s7928